RU2015132860A - Композиции инсулинов длительного действия - Google Patents
Композиции инсулинов длительного действия Download PDFInfo
- Publication number
- RU2015132860A RU2015132860A RU2015132860A RU2015132860A RU2015132860A RU 2015132860 A RU2015132860 A RU 2015132860A RU 2015132860 A RU2015132860 A RU 2015132860A RU 2015132860 A RU2015132860 A RU 2015132860A RU 2015132860 A RU2015132860 A RU 2015132860A
- Authority
- RU
- Russia
- Prior art keywords
- water
- pharmaceutical composition
- composition according
- based pharmaceutical
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Claims (18)
1. Фармацевтическая композиция на водной основе, содержащая 270-330 Ед/мл инсулина гларгина (эквимолярно 270-330 МЕ человеческого инсулина] при условии, что концентрация в указанной композиции не равна 300 ЕД/мл инсулина гларгина.
2. Фармацевтическая композиция на водной основе по п. 1, содержащая аналог эксендина-4.
3. Фармацевтическая композиция на водной основе по п. 2, где аналог эксендина-4 выбран из группы, состоящей из ликсисенатида, экзенатида и лираглутидом.
4. Фармацевтическая композиция на водной основе по п. 3, содержащая от 0,1 мкг до 10 мкг ликсисенатида на Ед инсулина гларгина.
5. Фармацевтическая композиция на водной основе по п. 4, содержащая от 0,2 мкг до 1 мкг ликсисенатида на Ед инсулина гларгина.
6. Фармацевтическая композиция на водной основе по п. 5, содержащая от 0,25 мкг до 0,7 мкг ликсисенатида на Ед инсулина гларгина.
7. Фармацевтическая композиция на водной основе по п. 1, содержащая один или несколько наполнителей, выбранных из группы, включающей цинк, м-крезол, глицерин, полисорбат 20 и натрий.
8. Фармацевтическая композиция на водной основе по п. 7, содержащая 90 мкг/мл цинка, 2,7 мг/мл м-крезола и 20 мг/мл глицерина 85%.
9. Фармацевтическая композиция на водной основе по п. 7, содержащая 90 мкг/мл цинка, 2,7 мг/мл м-крезола, 20 мкг/мл
полисорбата 20 и 20 мг/мл глицерина 85%.
10. Фармацевтическая композиция на водной основе по п. 1, где рН составляет от 3,4 до 4,6.
11. Фармацевтическая композиция на водной основе по п. 10, где рН составляет 4.
12. Фармацевтическая композиция на водной основе по п. 10, где рН составляет 4,5.
13. Фармацевтическая композиция на водной основе по п. 1 для лечения сахарного диабета типа I и типа II у пациента.
14. Фармацевтическая композиция на водной основе по п. 1 для увеличение продолжительности воздействия инсулина длительного действия при лечении сахарного диабета типа I и типа II у пациента.
15. Фармацевтическая композиция на водной основе по п. 1 для снижения частоты гипогликемии при лечении сахарного диабета типа I и типа II у пациента.
16. Фармацевтическая композиция на водной основе по п. 1 для обеспечения базального инсулина безпикового длительного действия при лечении типа I и типа II сахарного диабета у пациента.
17. Применение фармацевтической композиции на водной основе по любому из пп. 1-16 для получения лекарственного средства для лечения сахарного диабета типа I и сахарного диабета типа II.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305532 | 2010-05-19 | ||
EP10305532.3 | 2010-05-19 | ||
EP10305780.8 | 2010-07-13 | ||
EP10305780 | 2010-07-13 | ||
EP11305140 | 2011-02-10 | ||
EP11305140.3 | 2011-02-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011119988/15A Division RU2564104C2 (ru) | 2010-05-19 | 2011-05-18 | Композиции инсулинов длительного действия |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017146048A Division RU2017146048A (ru) | 2010-05-19 | 2017-12-27 | Композиции инсулинов длительного действия |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015132860A true RU2015132860A (ru) | 2017-02-09 |
RU2642662C2 RU2642662C2 (ru) | 2018-01-25 |
Family
ID=44148980
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011119988/15A RU2564104C2 (ru) | 2010-05-19 | 2011-05-18 | Композиции инсулинов длительного действия |
RU2015132860A RU2642662C2 (ru) | 2010-05-19 | 2015-08-06 | Композиции инсулинов длительного действия |
RU2017146048A RU2017146048A (ru) | 2010-05-19 | 2017-12-27 | Композиции инсулинов длительного действия |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011119988/15A RU2564104C2 (ru) | 2010-05-19 | 2011-05-18 | Композиции инсулинов длительного действия |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017146048A RU2017146048A (ru) | 2010-05-19 | 2017-12-27 | Композиции инсулинов длительного действия |
Country Status (43)
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1969004T3 (pl) | 2005-12-28 | 2012-01-31 | Novo Nordisk As | Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji |
MY152979A (en) | 2008-01-09 | 2014-12-15 | Sanofi Aventis Deutschland | Novel insulin derivatives having an extremely delayed time-action profile |
LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
JP4959005B2 (ja) | 2008-10-30 | 2012-06-20 | ノボ・ノルデイスク・エー/エス | 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療 |
SG10201403840VA (en) * | 2009-07-06 | 2014-10-30 | Sanofi Aventis Deutschland | Aqueous insulin preparations containing methionine |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
TWI468171B (zh) | 2009-11-13 | 2015-01-11 | Sanofi Aventis Deutschland | 含glp-1激動劑及甲硫胺酸之醫藥組成物 |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
AR084938A1 (es) | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
FR2984749A1 (fr) * | 2011-12-23 | 2013-06-28 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique |
EP2741765B9 (fr) | 2011-08-10 | 2016-09-28 | Adocia | Solution injectable d'au moins une insuline basale |
JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
FR2985429B1 (fr) * | 2012-01-09 | 2016-07-29 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle |
BR112014016889A8 (pt) | 2012-01-09 | 2017-07-04 | Adocia | composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8 |
FR2985428B1 (fr) * | 2012-01-09 | 2016-05-27 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue |
GB2513805B (en) | 2012-04-18 | 2020-04-01 | Waters Technologies Corp | Methods for quantifying polypeptides using mass spectrometry |
AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
FR3001896B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise |
US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
FR3001895B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes |
WO2014096985A2 (en) * | 2012-12-19 | 2014-06-26 | Wockhardt Limited | A stable aqueous composition comprising human insulin or an analogue or derivative thereof |
SI2934567T1 (sl) | 2012-12-21 | 2018-10-30 | Sanofi | Derivati eksendina-4 kot dualni GLP1/GIP ali trigonalni agonisti GLP1/GIP/glukagon |
CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
AU2013368990B2 (en) * | 2012-12-26 | 2017-05-18 | Wockhardt Limited | Pharmaceutical composition |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
WO2014147141A1 (en) * | 2013-03-20 | 2014-09-25 | Novo Nordisk A/S | Insulin dosing regimen |
RU2019133674A (ru) * | 2013-04-03 | 2020-05-20 | Санофи | Лечение сахарного диабета с помощью составов инсулинов длительного действия |
US20220202711A1 (en) * | 2013-04-03 | 2022-06-30 | Sanofi | Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins |
JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー/エス | 新規投与レジメン |
PT3010530T (pt) * | 2013-06-17 | 2019-04-18 | Sanofi Aventis Deutschland | Formulação de proporção fixa de insulina glargina/lixisenatido |
CN104587455A (zh) * | 2013-10-31 | 2015-05-06 | 江苏万邦生化医药股份有限公司 | 一种胰岛素制剂 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
AU2015205624A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
RU2016132386A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных |
RU2016132340A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулина аспарта |
CN103830189A (zh) * | 2014-03-04 | 2014-06-04 | 山东新时代药业有限公司 | 一种重组甘精胰岛素制剂及其制备方法 |
TW201625605A (zh) | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為gpr119調節劑的經取代之稠合雜環類 |
AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
WO2015150563A1 (en) | 2014-04-04 | 2015-10-08 | Sanofi | Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
WO2016001862A1 (en) | 2014-07-04 | 2016-01-07 | Wockhardt Limited | Extended release formulations of insulins |
KR20240017117A (ko) | 2014-07-16 | 2024-02-06 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
CR20170314A (es) * | 2014-12-12 | 2017-10-20 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
CN104688677B (zh) * | 2015-02-05 | 2018-02-09 | 通化东宝药业股份有限公司 | 一种稳定的甘精胰岛素注射液及其制备方法 |
CN104688678B (zh) * | 2015-02-05 | 2017-11-17 | 通化东宝药业股份有限公司 | 一种甘精胰岛素注射液的制备方法及其制备的甘精胰岛素注射液 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
AU2016308111A1 (en) | 2015-08-18 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
EA039114B1 (ru) * | 2015-11-10 | 2021-12-06 | Санофи-Авентис Дойчланд Гмбх | Применение композиции с постоянным соотношением инсулин гларгин/ликсисенатид для лечения сахарного диабета 2 типа |
TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Fgf21變異體 |
CN105597087B (zh) * | 2016-01-06 | 2019-04-26 | 山东新时代药业有限公司 | 一种甘精胰岛素注射液及其制备方法 |
GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
WO2018055539A1 (en) | 2016-09-22 | 2018-03-29 | Wockhardt Limited | Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
TW201833132A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為肽類glp1/升糖素/gip三重受體激動劑之新穎化合物 |
TW201833131A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為胜肽類glp1/升糖素/gip受體促效劑之新化合物 |
CA3047862A1 (en) | 2016-12-22 | 2018-06-28 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
US20190031774A1 (en) | 2017-06-09 | 2019-01-31 | Sanofi Biotechnology | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
AU2018308692A1 (en) * | 2017-07-27 | 2020-03-05 | Adocia | Compositions in the form of an injectable aqueous solution comprising at least human insulin A21G and a prandial action glucagon suppressor |
UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
US20210275643A1 (en) | 2018-06-21 | 2021-09-09 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
WO2019243628A1 (fr) | 2018-06-22 | 2019-12-26 | Adocia | Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
WO2020239837A1 (en) | 2019-05-29 | 2020-12-03 | Sanofi | Drug delivery device |
CN115811970A (zh) * | 2020-05-22 | 2023-03-17 | 韩美药品株式会社 | 胰高血糖素、glp-1和gip三重激动剂的长效缀合物的液体制剂 |
JP2023540663A (ja) | 2020-07-02 | 2023-09-26 | サノフイ | Glp-1rアゴニスト/fgf21融合タンパク質 |
JP2023540662A (ja) | 2020-07-02 | 2023-09-26 | サノフイ | 低減された活性を有するglp-1rアゴニストペプチド |
US20230302095A1 (en) * | 2020-08-14 | 2023-09-28 | Kyon Biotech Ag | Increasing the efficacy of biological therapeutic molecules |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4960702A (en) | 1985-09-06 | 1990-10-02 | Codon | Methods for recovery of tissue plasminogen activator |
PH23446A (en) | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
CH682806A5 (de) * | 1992-02-21 | 1993-11-30 | Medimpex Ets | Injektionsgerät. |
CH682805A5 (de) * | 1992-02-24 | 1993-11-30 | Medimpex Ets | Anzeigeeinrichtung für ein Injektionsgerät. |
DK0748213T3 (da) | 1994-03-07 | 2004-08-02 | Nektar Therapeutics | Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin |
AR002976A1 (es) * | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
PE79099A1 (es) | 1997-06-13 | 1999-08-24 | Lilly Co Eli | Formulaciones de insulina estables |
JP2001521004A (ja) | 1997-10-24 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | 脂肪酸−アシル化インスリン類似体 |
US6978471B1 (en) | 1999-05-25 | 2005-12-20 | Thomson Licensing S.A. | System for acquiring and processing broadcast programs and program guide data |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
ES2310192T3 (es) | 2000-09-18 | 2009-01-01 | Sanos Bioscience A/S | Uso de peptidos glp-2. |
US6852694B2 (en) | 2001-02-21 | 2005-02-08 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
US20030026872A1 (en) | 2001-05-11 | 2003-02-06 | The Procter & Gamble Co. | Compositions having enhanced aqueous solubility and methods of their preparation |
FR2827604B1 (fr) | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
MXPA04001560A (es) * | 2001-08-28 | 2004-05-17 | Lilly Co Eli | Premezclas de glp-1 e insulina basal. |
US20100069293A1 (en) | 2002-02-27 | 2010-03-18 | Pharmain Corporation | Polymeric carrier compositions for delivery of active agents, methods of making and using the same |
US7115563B2 (en) | 2002-05-29 | 2006-10-03 | Insignion Holding Limited | Composition and its therapeutic use |
DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
JP5685355B2 (ja) | 2002-07-04 | 2015-03-18 | ジーランド ファーマ アクティーゼルスカブ | Glp−1および糖尿病の処置方法 |
DE10235168A1 (de) | 2002-08-01 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Verfahren zur Reinigung von Preproinsulin |
GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
CA2498224C (en) | 2003-01-21 | 2011-03-22 | Ortho-Tain Inc. | A dental appliance and a system and a method for reducing an amount of patient cooperation to treat a malocclusion using the dental appliance |
GB0304822D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
US7544656B2 (en) | 2003-03-04 | 2009-06-09 | The Technology Development Company, Ltd. | Long acting injectable insulin composition and methods of making and using thereof |
JP2007504167A (ja) | 2003-08-29 | 2007-03-01 | セントカー・インコーポレーテツド | 抗組織因子抗体を用いる移植片の生存を向上する方法 |
ATE483580T1 (de) * | 2003-12-22 | 2010-10-15 | Novo Nordisk As | Durchsichtiger, flexibler, undurchlässiger kunststoffbehälter zur lagerung von pharmazeutischen flüssigkeiten |
US7192919B2 (en) | 2004-01-07 | 2007-03-20 | Stelios Tzannis | Sustained release compositions for delivery of pharmaceutical proteins |
SG151315A1 (en) | 2004-03-31 | 2009-04-30 | Centocor Inc | Human glp-1 mimetibodies, compositions, methods and uses |
AU2005337493A1 (en) | 2004-12-22 | 2007-04-26 | Centocor, Inc. | GLP-1 agonists, compositions, methods and uses |
US7879361B2 (en) | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for drug delivery |
EP1945142B1 (en) | 2005-09-26 | 2013-12-25 | Medtronic, Inc. | Prosthetic cardiac and venous valves |
US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
EP1940243B1 (en) | 2005-10-24 | 2011-08-03 | Nestec S.A. | Dietary fiber formulation and method of administration |
JP2009517410A (ja) | 2005-11-30 | 2009-04-30 | ジェネレクス ファーマシューティカルズ インコーポレイテッド | 経口吸収される医薬製剤および投与方法 |
US20100029558A1 (en) | 2005-12-06 | 2010-02-04 | Bristow Cynthia L | Alpha1 proteinase inhibitor peptides methods and use |
CN101454019A (zh) * | 2006-04-12 | 2009-06-10 | 百达尔公司 | 速效和长效胰岛素联合制剂 |
US20090099064A1 (en) | 2006-06-08 | 2009-04-16 | Diabecore Medical Inc., | Derivatized insulin oligomers |
DE102006031962A1 (de) * | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
EP2076242B8 (en) * | 2006-07-27 | 2013-02-20 | Nektar Therapeutics | Aerosolizable formulation comprising insulin for pulmonary delivery |
WO2008124522A2 (en) | 2007-04-04 | 2008-10-16 | Biodel, Inc. | Amylin formulations |
WO2009023566A2 (en) | 2007-08-09 | 2009-02-19 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
CN101778862B (zh) | 2007-08-13 | 2014-12-17 | 诺沃-诺迪斯克有限公司 | 快速作用的胰岛素类似物 |
PL2597103T3 (pl) | 2007-11-16 | 2017-04-28 | Novo Nordisk A/S | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
WO2009089181A1 (en) * | 2008-01-04 | 2009-07-16 | Blodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
MY161892A (en) | 2008-02-19 | 2017-05-15 | Biocon Ltd | A method of obtaining a purified, biologically active heterologous protein |
US8329419B2 (en) | 2008-05-23 | 2012-12-11 | Amylin Pharmaceuticals, Llc | GLP-1 receptor agonist bioassays |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
WO2010028055A1 (en) | 2008-09-02 | 2010-03-11 | Biodel, Inc. | Insulin with a basal release profile |
LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
DE102008053048A1 (de) * | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
JP4959005B2 (ja) | 2008-10-30 | 2012-06-20 | ノボ・ノルデイスク・エー/エス | 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療 |
US20120094894A1 (en) | 2009-02-13 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
US8709400B2 (en) | 2009-07-27 | 2014-04-29 | Washington University | Inducement of organogenetic tolerance for pancreatic xenotransplant |
NZ597964A (en) | 2009-07-31 | 2014-04-30 | Sanofi Aventis Deutschland | Long acting insulin composition |
TWI468171B (zh) | 2009-11-13 | 2015-01-11 | Sanofi Aventis Deutschland | 含glp-1激動劑及甲硫胺酸之醫藥組成物 |
ME01546B (me) | 2009-11-13 | 2014-04-20 | Sanofi Aventis Deutschland | Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2 |
ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
US20110118178A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
US20110118180A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
WO2011075623A1 (en) | 2009-12-18 | 2011-06-23 | Latitude Pharmaceuticals, Inc. | One - phase gel compos ition compri s ing phos pholi pids |
EA201201164A1 (ru) | 2010-02-22 | 2013-04-30 | Кейз Вестерн Ризев Юнивесити | Препараты на основе аналогов инсулина пролонгированного действия в растворимой и кристаллической формах |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
AR080884A1 (es) | 2010-04-14 | 2012-05-16 | Sanofi Aventis | Conjugados de insulina-sirna |
US8637458B2 (en) | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
WO2011144674A2 (en) | 2010-05-20 | 2011-11-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD |
EP2389945A1 (en) | 2010-05-28 | 2011-11-30 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising AVE0010 and insulin glargine |
US9085757B2 (en) | 2010-06-17 | 2015-07-21 | Regents Of The University Of Minnesota | Production of insulin producing cells |
US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
WO2012055967A2 (en) | 2010-10-27 | 2012-05-03 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections administered with varying injection intervals |
WO2012065996A1 (en) | 2010-11-15 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN |
WO2012066086A1 (en) | 2010-11-17 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN |
CA2825162A1 (en) | 2011-02-02 | 2012-08-09 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
EP2683406B1 (en) | 2011-03-11 | 2019-05-08 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
US20130096059A1 (en) | 2011-10-04 | 2013-04-18 | Jens Stechl | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract |
-
2011
- 2011-05-16 AU AU2011202239A patent/AU2011202239C1/en active Active
- 2011-05-17 UY UY0001033391A patent/UY33391A/es active IP Right Grant
- 2011-05-17 EP EP19184732.6A patent/EP3636250A1/en not_active Withdrawn
- 2011-05-17 DK DK11166415.7T patent/DK2387989T3/da active
- 2011-05-17 EP EP11166415.7A patent/EP2387989B1/en active Active
- 2011-05-17 TW TW100117134A patent/TWI469787B/zh active
- 2011-05-17 JO JO2011163A patent/JO2944B1/en active
- 2011-05-17 EP EP23157670.3A patent/EP4218723A3/en active Pending
- 2011-05-17 AR ARP110101688A patent/AR081200A1/es not_active Application Discontinuation
- 2011-05-17 TW TW104116749A patent/TWI605825B/zh active
- 2011-05-17 ES ES20199940T patent/ES2945208T3/es active Active
- 2011-05-17 EP EP18161680.6A patent/EP3424491A1/en not_active Withdrawn
- 2011-05-17 PL PL20199940.6T patent/PL3824876T3/pl unknown
- 2011-05-17 TW TW106106304A patent/TW201735941A/zh unknown
- 2011-05-17 LT LTEP14166877.2T patent/LT2781212T/lt unknown
- 2011-05-17 TR TR2018/09475T patent/TR201809475T4/tr unknown
- 2011-05-17 EP EP20199940.6A patent/EP3824876B8/en active Active
- 2011-05-17 PT PT111664157T patent/PT2387989E/pt unknown
- 2011-05-17 SI SI201131519T patent/SI2781212T1/en unknown
- 2011-05-17 JP JP2011110037A patent/JP5269945B2/ja active Active
- 2011-05-17 PL PL14166877T patent/PL2781212T3/pl unknown
- 2011-05-17 RS RSP20140522 patent/RS53559B1/en unknown
- 2011-05-17 HU HUE14166877A patent/HUE039355T2/hu unknown
- 2011-05-17 ES ES14166877.2T patent/ES2676401T3/es active Active
- 2011-05-17 EP EP14166877.2A patent/EP2781212B1/en active Active
- 2011-05-17 ES ES11166415.7T patent/ES2509943T3/es active Active
- 2011-05-17 PT PT141668772T patent/PT2781212T/pt unknown
- 2011-05-17 DK DK14166877.2T patent/DK2781212T3/en active
- 2011-05-17 PL PL11166415T patent/PL2387989T3/pl unknown
- 2011-05-17 TW TW103110412A patent/TWI496580B/zh active
- 2011-05-17 SI SI201130267T patent/SI2387989T1/sl unknown
- 2011-05-18 WO PCT/EP2011/058079 patent/WO2011144673A2/en active Application Filing
- 2011-05-18 TR TR2018/09514T patent/TR201809514T4/tr unknown
- 2011-05-18 SG SG10201510406YA patent/SG10201510406YA/en unknown
- 2011-05-18 CA CA2792669A patent/CA2792669C/en active Active
- 2011-05-18 KR KR1020187021814A patent/KR101989343B1/ko active IP Right Grant
- 2011-05-18 RU RU2011119988/15A patent/RU2564104C2/ru active
- 2011-05-18 KR KR1020177016698A patent/KR20170072960A/ko active Search and Examination
- 2011-05-18 HU HUE11720115A patent/HUE039354T2/hu unknown
- 2011-05-18 SG SG2012084208A patent/SG185593A1/en unknown
- 2011-05-18 PT PT117201152T patent/PT2571517T/pt unknown
- 2011-05-18 BR BR112012029131-9A patent/BR112012029131B1/pt active IP Right Grant
- 2011-05-18 EP EP18155758.8A patent/EP3400931A1/en not_active Withdrawn
- 2011-05-18 NZ NZ602541A patent/NZ602541A/xx unknown
- 2011-05-18 MA MA35358A patent/MA34224B1/fr unknown
- 2011-05-18 KR KR1020147023925A patent/KR101913672B1/ko active IP Right Grant
- 2011-05-18 SI SI201131518T patent/SI2571517T1/en unknown
- 2011-05-18 PE PE2012002170A patent/PE20130511A1/es active IP Right Grant
- 2011-05-18 EP EP11720115.2A patent/EP2571517B1/en active Active
- 2011-05-18 PL PL11720115T patent/PL2571517T3/pl unknown
- 2011-05-18 LT LTEP11720115.2T patent/LT2571517T/lt unknown
- 2011-05-18 PE PE2016000735A patent/PE20160781A1/es unknown
- 2011-05-18 BR BR122019006884-4A patent/BR122019006884B1/pt active IP Right Grant
- 2011-05-18 US US13/110,568 patent/US20110301081A1/en not_active Abandoned
- 2011-05-18 EP EP19174460.6A patent/EP3607935A1/en not_active Withdrawn
- 2011-05-18 MY MYPI2012004140A patent/MY156188A/en unknown
- 2011-05-18 MX MX2012011278A patent/MX343489B/es active IP Right Grant
- 2011-05-18 DK DK11720115.2T patent/DK2571517T3/en active
- 2011-05-18 ES ES11720115.2T patent/ES2690302T3/es active Active
- 2011-05-18 KR KR1020127026802A patent/KR101486743B1/ko active IP Right Grant
- 2011-05-19 CN CN201710324824.8A patent/CN107583038A/zh active Pending
- 2011-05-19 CN CN201710249012.1A patent/CN107583037A/zh active Pending
- 2011-05-19 CN CN2011102251176A patent/CN102319422A/zh not_active Withdrawn
- 2011-05-19 CN CN201410818149.0A patent/CN104622788A/zh active Pending
- 2011-05-19 CN CN201410220537.9A patent/CN103948913A/zh active Pending
- 2011-12-02 US US13/310,118 patent/US20120122774A1/en not_active Abandoned
-
2012
- 2012-03-13 HK HK15111312.1A patent/HK1210435A1/xx unknown
- 2012-03-13 HK HK14111946A patent/HK1198428A1/xx unknown
- 2012-03-13 HK HK18108478.4A patent/HK1248592A1/zh unknown
- 2012-03-13 HK HK18108479.3A patent/HK1248593A1/zh unknown
- 2012-09-13 IL IL221964A patent/IL221964A/en active IP Right Grant
- 2012-09-18 ZA ZA2012/06998A patent/ZA201206998B/en unknown
- 2012-09-28 MX MX2019003693A patent/MX2019003693A/es unknown
- 2012-10-01 TN TNP2012000478A patent/TN2012000478A1/en unknown
- 2012-10-02 DO DO2012000261A patent/DOP2012000261A/es unknown
- 2012-10-03 NI NI201200152A patent/NI201200152A/es unknown
- 2012-10-23 GT GT201200287A patent/GT201200287A/es unknown
- 2012-11-08 CO CO12201607A patent/CO6640217A2/es unknown
- 2012-11-13 CR CR20120578A patent/CR20120578A/es unknown
- 2012-11-15 CL CL2012003197A patent/CL2012003197A1/es unknown
- 2012-11-16 EC ECSP12012298 patent/ECSP12012298A/es unknown
-
2013
- 2013-05-07 JP JP2013097274A patent/JP2013147509A/ja not_active Withdrawn
-
2014
- 2014-03-20 US US14/220,562 patent/US9345750B2/en active Active
- 2014-09-11 HR HRP20140860AT patent/HRP20140860T1/hr unknown
- 2014-10-15 CY CY20141100842T patent/CY1115649T1/el unknown
-
2015
- 2015-02-17 US US14/624,575 patent/US20150164999A1/en not_active Abandoned
- 2015-03-24 HK HK15102982.9A patent/HK1202428A1/xx unknown
- 2015-06-03 JP JP2015112917A patent/JP6333775B2/ja active Active
- 2015-06-19 PH PH12015501421A patent/PH12015501421A1/en unknown
- 2015-08-06 RU RU2015132860A patent/RU2642662C2/ru active
- 2015-10-07 JO JOP/2015/0245A patent/JOP20150245B1/ar active
-
2016
- 2016-04-20 US US15/134,152 patent/US20160228516A1/en not_active Abandoned
- 2016-05-23 US US15/162,563 patent/US20160339084A1/en not_active Abandoned
-
2017
- 2017-03-21 IL IL251318A patent/IL251318B/en active IP Right Grant
- 2017-12-13 JP JP2017238185A patent/JP2018044003A/ja active Pending
- 2017-12-27 RU RU2017146048A patent/RU2017146048A/ru unknown
-
2018
- 2018-07-04 CY CY20181100701T patent/CY1120407T1/el unknown
- 2018-07-04 CY CY181100700T patent/CY1121042T1/el unknown
- 2018-07-04 HR HRP20181028TT patent/HRP20181028T1/hr unknown
- 2018-07-04 HR HRP20181026TT patent/HRP20181026T1/hr unknown
- 2018-08-21 US US16/108,064 patent/US20190046616A1/en not_active Abandoned
-
2019
- 2019-03-11 PH PH12019500517A patent/PH12019500517A1/en unknown
- 2019-03-28 US US16/368,201 patent/US20190388511A1/en not_active Abandoned
- 2019-09-17 US US16/572,850 patent/US20200215163A1/en not_active Abandoned
- 2019-12-13 JP JP2019224977A patent/JP2020040990A/ja active Pending
-
2020
- 2020-05-13 US US15/930,643 patent/US20200384087A1/en not_active Abandoned
-
2021
- 2021-02-16 US US17/176,442 patent/US20210308225A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015132860A (ru) | Композиции инсулинов длительного действия | |
JP2011241213A5 (ru) | ||
RU2600440C3 (ru) | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты | |
RU2012123739A (ru) | Фармацевтическая композиция, содержащая агонист гпп-1 и метионин | |
RU2019133674A (ru) | Лечение сахарного диабета с помощью составов инсулинов длительного действия | |
RU2012124069A (ru) | Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин | |
RU2015137674A (ru) | Стабилизированные фармацевтические составы аналогов инсулина и/или производные инсулина | |
EA201892383A1 (ru) | Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина | |
NZ608829A (en) | Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof | |
RU2016132342A (ru) | Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных | |
RU2009146883A (ru) | Стабильные неводные фармацевтические композиции | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
RU2016132340A (ru) | Стабилизированные фармацевтические составы на основе инсулина аспарта | |
CY1113755T1 (el) | Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2 | |
RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
MX2013008374A (es) | Apolipoproteina a-iv como un peptido antidiabetico. | |
JP2014504601A5 (ru) | ||
NZ602583A (en) | Methods of using diacerein as an adjunctive therapy for diabetes | |
RU2022119802A (ru) | Композиции инсулинов длительного действия | |
JP2007513059A5 (ru) | ||
RU2019128331A (ru) | Стабилизированные фармацевтические составы аналогов инсулина и/или производные инсулина | |
Dumanov et al. | Injection drugs for treatment of diabetes mellitus type II | |
TR201700016A1 (tr) | Parenteral farmasöti̇k bi̇leşi̇mler | |
RU2008151796A (ru) | Способ профилактики желудочно-кишечных заболеваний у поросят-отъемышей | |
EA200800281A1 (ru) | Способ коррекции экспериментального миокардита с помощью мицеллярной формы интерферона альфа |